BR112015009954A2 - Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kit - Google Patents
Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kitInfo
- Publication number
- BR112015009954A2 BR112015009954A2 BR112015009954A BR112015009954A BR112015009954A2 BR 112015009954 A2 BR112015009954 A2 BR 112015009954A2 BR 112015009954 A BR112015009954 A BR 112015009954A BR 112015009954 A BR112015009954 A BR 112015009954A BR 112015009954 A2 BR112015009954 A2 BR 112015009954A2
- Authority
- BR
- Brazil
- Prior art keywords
- erfe
- polypeptide
- kit
- nucleic acid
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721322P | 2012-11-01 | 2012-11-01 | |
| PCT/US2013/067771 WO2014071015A1 (en) | 2012-11-01 | 2013-10-31 | Erythroferrone and erfe polypeptides and methods of regulating iron metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015009954A2 true BR112015009954A2 (pt) | 2017-08-22 |
Family
ID=50628048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015009954A BR112015009954A2 (pt) | 2012-11-01 | 2013-10-31 | Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kit |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160122409A1 (https=) |
| EP (1) | EP2914619B1 (https=) |
| JP (1) | JP6501362B2 (https=) |
| KR (1) | KR102186218B1 (https=) |
| CN (1) | CN104854130A (https=) |
| AU (1) | AU2013337808B2 (https=) |
| BR (1) | BR112015009954A2 (https=) |
| CA (1) | CA2890040A1 (https=) |
| ES (1) | ES2731609T3 (https=) |
| RU (1) | RU2684216C2 (https=) |
| WO (1) | WO2014071015A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109414468B (zh) * | 2016-04-27 | 2021-09-10 | 弗拉基米尔·巴德玛耶夫 | 利用姜烯酚维持体内铁质平衡的方法 |
| WO2018027184A1 (en) * | 2016-08-05 | 2018-02-08 | Silarus Therapeutics, Inc. | Erfe specific antibodies compositions and methods of use |
| US20200040054A1 (en) * | 2016-10-03 | 2020-02-06 | Silarus Therapeutics, Inc. | Erfe fusion polypeptides compositions and methods of use |
| CN110636857B (zh) * | 2017-03-13 | 2024-04-30 | 因全惜客生命科学有限公司 | 人红富铁激素的抗体及其用途 |
| CA3063100A1 (en) * | 2017-05-16 | 2018-11-22 | Generos Biopharma Ltd. | Compositions and methods for treating rheumatoid arthritis |
| EP3634477A4 (en) * | 2017-06-06 | 2021-03-03 | The Regents of the University of California | IMMUNOLOGICAL DOSAGE FOR HUMAN ERYTHROFERRONE |
| WO2019148186A1 (en) * | 2018-01-29 | 2019-08-01 | Silarus Therapeutics, Inc. | Antibodies binding erfe and methods of use |
| WO2019212364A1 (en) * | 2018-05-01 | 2019-11-07 | Christopher Joseph Pemberton | Test for heart failure |
| CA3045370A1 (en) * | 2018-06-08 | 2019-12-08 | Pfizer Inc. | Methods of treating metabolic disease |
| JP2022522265A (ja) * | 2019-01-16 | 2022-04-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エリスロフェロンの変異体及びその使用 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JP2026506602A (ja) | 2023-02-13 | 2026-02-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 鉄過剰関連疾患の処置方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2506668C (en) * | 2002-11-19 | 2014-08-19 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| GB0423973D0 (en) * | 2004-10-28 | 2004-12-01 | Ares Trading Sa | C1q related points |
| US7968091B2 (en) * | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| GB0818273D0 (en) * | 2008-10-06 | 2008-11-12 | Cambridge Entpr Ltd | Modulation of cellular activity and differentiation |
| CN102245626A (zh) * | 2008-12-05 | 2011-11-16 | 加利福尼亚大学董事会 | 微型铁调素肽及其使用方法 |
| WO2013112663A1 (en) * | 2012-01-26 | 2013-08-01 | The Johns Hopkins University | Myonectin (ctrp15), compositions comprising same, and methods of use |
-
2013
- 2013-10-31 AU AU2013337808A patent/AU2013337808B2/en not_active Ceased
- 2013-10-31 RU RU2015120601A patent/RU2684216C2/ru active
- 2013-10-31 KR KR1020157013416A patent/KR102186218B1/ko not_active Expired - Fee Related
- 2013-10-31 JP JP2015540784A patent/JP6501362B2/ja not_active Expired - Fee Related
- 2013-10-31 CN CN201380065041.2A patent/CN104854130A/zh active Pending
- 2013-10-31 WO PCT/US2013/067771 patent/WO2014071015A1/en not_active Ceased
- 2013-10-31 BR BR112015009954A patent/BR112015009954A2/pt not_active Application Discontinuation
- 2013-10-31 CA CA2890040A patent/CA2890040A1/en not_active Abandoned
- 2013-10-31 ES ES13851277T patent/ES2731609T3/es active Active
- 2013-10-31 EP EP13851277.7A patent/EP2914619B1/en not_active Not-in-force
-
2015
- 2015-04-28 US US14/698,608 patent/US20160122409A1/en not_active Abandoned
-
2018
- 2018-06-01 US US15/996,152 patent/US20180355008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2684216C2 (ru) | 2019-04-04 |
| ES2731609T3 (es) | 2019-11-18 |
| KR102186218B1 (ko) | 2020-12-03 |
| JP6501362B2 (ja) | 2019-04-17 |
| AU2013337808A1 (en) | 2015-05-14 |
| CN104854130A (zh) | 2015-08-19 |
| KR20150077471A (ko) | 2015-07-07 |
| WO2014071015A1 (en) | 2014-05-08 |
| US20180355008A1 (en) | 2018-12-13 |
| EP2914619A1 (en) | 2015-09-09 |
| AU2013337808B2 (en) | 2017-12-21 |
| JP2015536337A (ja) | 2015-12-21 |
| EP2914619B1 (en) | 2019-05-29 |
| CA2890040A1 (en) | 2014-05-08 |
| RU2015120601A (ru) | 2016-12-20 |
| EP2914619A4 (en) | 2016-05-11 |
| US20160122409A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015009954A2 (pt) | Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kit | |
| BR112018071307A2 (pt) | anticorpos agonistas que ligam cd40 humana e usos dos mesmos | |
| WO2018226578A8 (en) | Nectin-4 binding proteins and methods of use thereof | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| WO2018026819A3 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
| UA112416C2 (uk) | Антитіло до fap і способи його застосування | |
| BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
| BR112014020826A8 (pt) | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| BR112017025813A2 (pt) | método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana | |
| CR20180068A (es) | Constructos de anticuerpo para cd70 y cd3 | |
| BR112014027128A2 (pt) | antígenos associados à próstata e regimes de imunoterapia baseada em vacina | |
| BR112015008311A2 (pt) | conjugados fármaco-proteína | |
| BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
| BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| MX384075B (es) | Nuevas proteínas específicas para la angiogénesis. | |
| UY34527A (es) | ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?. | |
| UA99339C2 (ru) | Антитело, которое специфично связывает человеческий tyrp1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |